<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157569</url>
  </required_header>
  <id_info>
    <org_study_id>NavyGHB-006</org_study_id>
    <nct_id>NCT04157569</nct_id>
  </id_info>
  <brief_title>CtDNA After Chemotherapy in Elderly Patients With Acute Leukemia</brief_title>
  <official_title>Monitoring Circulating Tumor DNA After Chemotherapy in Elderly Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navy General Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navy General Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will monitor CtDNA After Chemotherapy in Elderly Patients With AL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will use droplet digital PCR (ddPCR) method to quantify peripheral blood plasma
      mutant allele frequency (MAF) in elderly acute leukemia patients after chemotherapy to
      evaluate the clinical value of CtDNA .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative incidence of relapse(CIR)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>cumulative incidence of relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Leukemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venipuncture peripheral blood bone marrow finger stick peripheral blood saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population include old AML patients with somatic mutations
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Male

          -  not pregnant female

          -  patients &gt;=60 years old

          -  Diagnosis of acute leukemia

        Exclusion Criteria:

          -  Pregnancy

          -  HIV positive

          -  patients &gt;=100 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liren Qian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Navy General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liren Qian, MD</last_name>
    <phone>+861066957676</phone>
    <email>qlr2007@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liren Qian, M.D.</last_name>
      <phone>+861066957676</phone>
      <email>qlr2007@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Navy General Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Liren Qian</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

